{"id":271,"date":"2019-12-08T22:18:59","date_gmt":"2019-12-09T03:18:59","guid":{"rendered":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/chapter\/6-8-antianginal-nitrates\/"},"modified":"2022-02-25T10:00:05","modified_gmt":"2022-02-25T15:00:05","slug":"6-8-antianginal-nitrates","status":"publish","type":"chapter","link":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/chapter\/6-8-antianginal-nitrates\/","title":{"raw":"6.8 Antianginal Drugs","rendered":"6.8 Antianginal Drugs"},"content":{"raw":"<h3>Antianginal Drugs<\/h3>\r\nAntianginal drugs are used to treat angina pectoris. Angina is chest pain caused by inadequate blood flow, resulting in hypoxia of the cardiac tissue. Angina can be chronic pain caused by atherosclerosis in coronary artery disease or acute pain caused by a myocardial infarction.\r\n\r\nAntianginals increase blood flow to the heart or decrease oxygen demand by the heart. Nitrates promote vasodilation of coronary arteries and veins. Beta blockers and calcium channel blockers are also used to decrease the workload of the heart and oxygen demands.\r\n\r\nNitrates may be administered through a variety of routes, such as sublingual, extended-release tablets, creams, transdermal patches, and intravenously. The grid below focuses on administration via sublingual tablets. Sublingual tablets are prescribed PRN (\u201cas needed\u201d) for clients who are experiencing chronic, stable angina due to coronary artery disease.\r\n\r\n<strong>Mechanism of Action<\/strong>\r\n\r\nNitroglycerin relieves angina by relaxing vascular smooth muscle, resulting in vasodilation.\r\n\r\n<strong>Indications for Use<\/strong>\r\n\r\nNitroglycerin is used to relieve angina due to coronary artery disease, during times of an acute attack, or prophylactically.\r\n\r\n<strong>Nursing Considerations Across the Lifespan<\/strong>\r\n\r\nClients taking sildenafil (Viagra) or similar medications for erectile dysfunction in the previous 24 hours may not take nitroglycerin as this may result in a dangerous drop in blood pressure.\r\n\r\nNitroglycerin should not be used in pregnant women or those who are breastfeeding.\r\n\r\nNitroglycerin is contraindicated in clients who have severe anemia, increased intracranial pressure, hypersensitivity, or circulatory failure.\r\n\r\n<strong>Adverse\/Side Effects<\/strong>\r\n\r\nClients taking nitroglycerin may experience hypotension, palpitations, headache, weakness, sweating, flushing, nausea, vomiting, or dizziness.\r\n\r\nClients should allow medication to dissolve under their tongue. This route allows immediate absorption into the circulation and avoids first-pass metabolism by the liver. Clients may take up to one sublingual tablet every 5 minutes, to a maximum of 3 tablets within 15 minutes, to relieve chest pain. If chest pain is not relieved after the first dose, 911 should be called. Nitroglycerin may also be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.\r\n\r\n<strong>Client Teaching &amp; Education<\/strong>\r\n\r\nInstruct client to avoid eating or smoking during administration as this may alter absorption. Clients should sit during administration to decrease the risk for injury due to the possibility of hypotension, dizziness, and weakness. Nitroglycerin decomposes when exposed to heat or light, so it should be stored in the original, airtight glass container. See Figure 6.8<sup>[footnote]\"<a href=\"https:\/\/commons.wikimedia.org\/wiki\/File:Nitroglycerin_(1).JPG\" target=\"_blank\" rel=\"noopener noreferrer\">Nitroglycerin (1).JPG\" <\/a>by <a href=\"https:\/\/commons.wikimedia.org\/wiki\/User:Intropin\" target=\"_blank\" rel=\"noopener noreferrer\">Intropin<\/a> is licensed under <a href=\"https:\/\/creativecommons.org\/licenses\/by\/3.0\/\" target=\"_blank\" rel=\"noopener noreferrer\">CC BY 3.0<\/a>[\/footnote]<\/sup> for an image of nitroglycerin containers.<sup>[footnote]This work is a derivative of <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" target=\"_blank\" rel=\"noopener noreferrer\">Daily Med<\/a> by <a href=\"https:\/\/www.nlm.nih.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a> in the<a href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" target=\"_blank\" rel=\"noopener noreferrer\"> public domain<\/a>. [\/footnote]<\/sup>\r\n\r\nHistorically, clients have been taught to seek emergency help (call 911) if pain persists after the 3rd dose of medication. However, new guidelines from the American Heart Association urge clients to call 911 after the first dose if symptoms are not improved or become worse.<sup>[footnote]O\u2019Gara, P., Kushner, F. , Ascheim, D. , Casey, D., Chung, M., de Lemos, J., Ettinger, S., Fang, J, Fesmire, F., Franklin, B., Granger, C., Krumholz, H., Linderbaum, J., Morrow, D., Newby, L., Ornato, J., Ou, N., Radford, M., Tamis-Holland, J., Tommaso, C., Tracy, C., Woo, Y., &amp; Zhao, D. (2013).\u00a0 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines. <em>Circulation, 127<\/em>(4). <a href=\"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIR.0b013e3182742cf6?url_ver=Z39.88-2003&amp;rfr_id=ori%3Arid%3Acrossref.org&amp;rfr_dat=cr_pub%3Dpubmed\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIR.0b013e3182742cf6?url_ver=Z39.88-2003&amp;rfr_id=ori%3Arid%3Acrossref.org&amp;rfr_dat=cr_pub%3Dpubmed<\/a> [\/footnote]<\/sup>\r\n\r\n[caption id=\"\" align=\"aligncenter\" width=\"232\"]<img title=\"&quot;Nitroglycerin (1).JPG&quot; by Intropin is licensed under CC BY 3.0\" src=\"https:\/\/pressbooks.bccampus.ca\/knowinghome\/wp-content\/uploads\/sites\/1167\/2019\/12\/image1-2.png\" alt=\"Photo showing a bottle containing nitroglycerin tablets\" width=\"232\" height=\"309\" \/> Figure 6.8 Sublingual nitroglycerin should be stored in its original, air tight glass container[\/caption]\r\n\r\nNow let's take a closer look at the medication card for nitroglycerin in Table 6.8.<sup>[footnote]This work is a derivative of\u00a0<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" target=\"_blank\" rel=\"noopener noreferrer\">Daily Med<\/a>\u00a0by\u00a0<a href=\"https:\/\/www.nlm.nih.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a>\u00a0in the\u00a0<a href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" target=\"_blank\" rel=\"noopener noreferrer\">public domain<\/a><span style=\"font-size: 1em\">. [\/footnote]<\/span><\/sup>\r\n\r\nTable 6.8 Nitroglycerine Medication Card\r\n\r\n<img class=\"alignnone wp-image-1667 size-full\" src=\"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/1167\/2019\/12\/Nitroglycerin.jpg\" alt=\"\" width=\"1700\" height=\"2200\" \/>\r\n<div class=\"__UNKNOWN__\">\r\n<div class=\"textbox textbox--examples\"><header class=\"textbox__header\">\r\n<h2>Clinical Reasoning and Decision-Making Activity 6.8a\r\n<img class=\"alignright wp-image-197\" src=\"https:\/\/pressbooks.bccampus.ca\/knowinghome\/wp-content\/uploads\/sites\/1167\/2019\/09\/ORN-Icons_lightbulb-300x300-1.png\" alt=\"Image of lightbulb in a circle\" width=\"200\" height=\"200\" \/><\/h2>\r\n<\/header>\r\n<div class=\"textbox__content\" style=\"text-align: left\">\r\n\r\nA client was administered the first dose of nitroglycerin at 1305hrs for acute angina.\u00a0 What should the nurse evaluate after administration?\r\n\r\nNote: Answers to the Critical Thinking activities can be found in the \"Answer Key\" sections at the end of the book.\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>","rendered":"<h3>Antianginal Drugs<\/h3>\n<p>Antianginal drugs are used to treat angina pectoris. Angina is chest pain caused by inadequate blood flow, resulting in hypoxia of the cardiac tissue. Angina can be chronic pain caused by atherosclerosis in coronary artery disease or acute pain caused by a myocardial infarction.<\/p>\n<p>Antianginals increase blood flow to the heart or decrease oxygen demand by the heart. Nitrates promote vasodilation of coronary arteries and veins. Beta blockers and calcium channel blockers are also used to decrease the workload of the heart and oxygen demands.<\/p>\n<p>Nitrates may be administered through a variety of routes, such as sublingual, extended-release tablets, creams, transdermal patches, and intravenously. The grid below focuses on administration via sublingual tablets. Sublingual tablets are prescribed PRN (\u201cas needed\u201d) for clients who are experiencing chronic, stable angina due to coronary artery disease.<\/p>\n<p><strong>Mechanism of Action<\/strong><\/p>\n<p>Nitroglycerin relieves angina by relaxing vascular smooth muscle, resulting in vasodilation.<\/p>\n<p><strong>Indications for Use<\/strong><\/p>\n<p>Nitroglycerin is used to relieve angina due to coronary artery disease, during times of an acute attack, or prophylactically.<\/p>\n<p><strong>Nursing Considerations Across the Lifespan<\/strong><\/p>\n<p>Clients taking sildenafil (Viagra) or similar medications for erectile dysfunction in the previous 24 hours may not take nitroglycerin as this may result in a dangerous drop in blood pressure.<\/p>\n<p>Nitroglycerin should not be used in pregnant women or those who are breastfeeding.<\/p>\n<p>Nitroglycerin is contraindicated in clients who have severe anemia, increased intracranial pressure, hypersensitivity, or circulatory failure.<\/p>\n<p><strong>Adverse\/Side Effects<\/strong><\/p>\n<p>Clients taking nitroglycerin may experience hypotension, palpitations, headache, weakness, sweating, flushing, nausea, vomiting, or dizziness.<\/p>\n<p>Clients should allow medication to dissolve under their tongue. This route allows immediate absorption into the circulation and avoids first-pass metabolism by the liver. Clients may take up to one sublingual tablet every 5 minutes, to a maximum of 3 tablets within 15 minutes, to relieve chest pain. If chest pain is not relieved after the first dose, 911 should be called. Nitroglycerin may also be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.<\/p>\n<p><strong>Client Teaching &amp; Education<\/strong><\/p>\n<p>Instruct client to avoid eating or smoking during administration as this may alter absorption. Clients should sit during administration to decrease the risk for injury due to the possibility of hypotension, dizziness, and weakness. Nitroglycerin decomposes when exposed to heat or light, so it should be stored in the original, airtight glass container. See Figure 6.8<sup><a class=\"footnote\" title=\"&quot;Nitroglycerin (1).JPG&quot; by Intropin is licensed under CC BY 3.0\" id=\"return-footnote-271-1\" href=\"#footnote-271-1\" aria-label=\"Footnote 1\"><sup class=\"footnote\">[1]<\/sup><\/a><\/sup> for an image of nitroglycerin containers.<sup><a class=\"footnote\" title=\"This work is a derivative of Daily Med by U.S. National Library of Medicine in the public domain.\" id=\"return-footnote-271-2\" href=\"#footnote-271-2\" aria-label=\"Footnote 2\"><sup class=\"footnote\">[2]<\/sup><\/a><\/sup><\/p>\n<p>Historically, clients have been taught to seek emergency help (call 911) if pain persists after the 3rd dose of medication. However, new guidelines from the American Heart Association urge clients to call 911 after the first dose if symptoms are not improved or become worse.<sup><a class=\"footnote\" title=\"O\u2019Gara, P., Kushner, F. , Ascheim, D. , Casey, D., Chung, M., de Lemos, J., Ettinger, S., Fang, J, Fesmire, F., Franklin, B., Granger, C., Krumholz, H., Linderbaum, J., Morrow, D., Newby, L., Ornato, J., Ou, N., Radford, M., Tamis-Holland, J., Tommaso, C., Tracy, C., Woo, Y., &amp; Zhao, D. (2013).\u00a0 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines. Circulation, 127(4). https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIR.0b013e3182742cf6?url_ver=Z39.88-2003&amp;rfr_id=ori%3Arid%3Acrossref.org&amp;rfr_dat=cr_pub%3Dpubmed\" id=\"return-footnote-271-3\" href=\"#footnote-271-3\" aria-label=\"Footnote 3\"><sup class=\"footnote\">[3]<\/sup><\/a><\/sup><\/p>\n<figure style=\"width: 232px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" title=\"&quot;Nitroglycerin (1).JPG&quot; by Intropin is licensed under CC BY 3.0\" src=\"https:\/\/pressbooks.bccampus.ca\/knowinghome\/wp-content\/uploads\/sites\/1167\/2019\/12\/image1-2.png\" alt=\"Photo showing a bottle containing nitroglycerin tablets\" width=\"232\" height=\"309\" \/><figcaption class=\"wp-caption-text\">Figure 6.8 Sublingual nitroglycerin should be stored in its original, air tight glass container<\/figcaption><\/figure>\n<p>Now let&#8217;s take a closer look at the medication card for nitroglycerin in Table 6.8.<sup><a class=\"footnote\" title=\"This work is a derivative of\u00a0Daily Med\u00a0by\u00a0U.S. National Library of Medicine\u00a0in the\u00a0public domain.\" id=\"return-footnote-271-4\" href=\"#footnote-271-4\" aria-label=\"Footnote 4\"><sup class=\"footnote\">[4]<\/sup><\/a><\/span><\/sup><\/p>\n<p>Table 6.8 Nitroglycerine Medication Card<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-1667 size-full\" src=\"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/1167\/2019\/12\/Nitroglycerin.jpg\" alt=\"\" width=\"1700\" height=\"2200\" srcset=\"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/1167\/2019\/12\/Nitroglycerin.jpg 1700w, https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/1167\/2019\/12\/Nitroglycerin-232x300.jpg 232w, https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/1167\/2019\/12\/Nitroglycerin-791x1024.jpg 791w, https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/1167\/2019\/12\/Nitroglycerin-768x994.jpg 768w, https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/1167\/2019\/12\/Nitroglycerin-1187x1536.jpg 1187w, https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/1167\/2019\/12\/Nitroglycerin-1583x2048.jpg 1583w, https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/1167\/2019\/12\/Nitroglycerin-65x84.jpg 65w, https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/1167\/2019\/12\/Nitroglycerin-225x291.jpg 225w, https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/1167\/2019\/12\/Nitroglycerin-350x453.jpg 350w\" sizes=\"auto, (max-width: 1700px) 100vw, 1700px\" \/><\/p>\n<div class=\"__UNKNOWN__\">\n<div class=\"textbox textbox--examples\">\n<header class=\"textbox__header\">\n<h2>Clinical Reasoning and Decision-Making Activity 6.8a<br \/>\n<img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-197\" src=\"https:\/\/pressbooks.bccampus.ca\/knowinghome\/wp-content\/uploads\/sites\/1167\/2019\/09\/ORN-Icons_lightbulb-300x300-1.png\" alt=\"Image of lightbulb in a circle\" width=\"200\" height=\"200\" \/><\/h2>\n<\/header>\n<div class=\"textbox__content\" style=\"text-align: left\">\n<p>A client was administered the first dose of nitroglycerin at 1305hrs for acute angina.\u00a0 What should the nurse evaluate after administration?<\/p>\n<p>Note: Answers to the Critical Thinking activities can be found in the &#8220;Answer Key&#8221; sections at the end of the book.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"media-attributions clear\" prefix:cc=\"http:\/\/creativecommons.org\/ns#\" prefix:dc=\"http:\/\/purl.org\/dc\/terms\/\"><h2>Media Attributions<\/h2><ul><li >Nitroglycerin       <\/li><\/ul><\/div><hr class=\"before-footnotes clear\" \/><div class=\"footnotes\"><ol><li id=\"footnote-271-1\">\"<a href=\"https:\/\/commons.wikimedia.org\/wiki\/File:Nitroglycerin_(1).JPG\" target=\"_blank\" rel=\"noopener noreferrer\">Nitroglycerin (1).JPG\" <\/a>by <a href=\"https:\/\/commons.wikimedia.org\/wiki\/User:Intropin\" target=\"_blank\" rel=\"noopener noreferrer\">Intropin<\/a> is licensed under <a href=\"https:\/\/creativecommons.org\/licenses\/by\/3.0\/\" target=\"_blank\" rel=\"noopener noreferrer\">CC BY 3.0<\/a> <a href=\"#return-footnote-271-1\" class=\"return-footnote\" aria-label=\"Return to footnote 1\">&crarr;<\/a><\/li><li id=\"footnote-271-2\">This work is a derivative of <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" target=\"_blank\" rel=\"noopener noreferrer\">Daily Med<\/a> by <a href=\"https:\/\/www.nlm.nih.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a> in the<a href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" target=\"_blank\" rel=\"noopener noreferrer\"> public domain<\/a>.  <a href=\"#return-footnote-271-2\" class=\"return-footnote\" aria-label=\"Return to footnote 2\">&crarr;<\/a><\/li><li id=\"footnote-271-3\">O\u2019Gara, P., Kushner, F. , Ascheim, D. , Casey, D., Chung, M., de Lemos, J., Ettinger, S., Fang, J, Fesmire, F., Franklin, B., Granger, C., Krumholz, H., Linderbaum, J., Morrow, D., Newby, L., Ornato, J., Ou, N., Radford, M., Tamis-Holland, J., Tommaso, C., Tracy, C., Woo, Y., &amp; Zhao, D. (2013).\u00a0 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines. <em>Circulation, 127<\/em>(4). <a href=\"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIR.0b013e3182742cf6?url_ver=Z39.88-2003&amp;rfr_id=ori%3Arid%3Acrossref.org&amp;rfr_dat=cr_pub%3Dpubmed\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIR.0b013e3182742cf6?url_ver=Z39.88-2003&amp;rfr_id=ori%3Arid%3Acrossref.org&amp;rfr_dat=cr_pub%3Dpubmed<\/a>  <a href=\"#return-footnote-271-3\" class=\"return-footnote\" aria-label=\"Return to footnote 3\">&crarr;<\/a><\/li><li id=\"footnote-271-4\">This work is a derivative of\u00a0<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" target=\"_blank\" rel=\"noopener noreferrer\">Daily Med<\/a>\u00a0by\u00a0<a href=\"https:\/\/www.nlm.nih.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a>\u00a0in the\u00a0<a href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" target=\"_blank\" rel=\"noopener noreferrer\">public domain<\/a><span style=\"font-size: 1em\">.  <a href=\"#return-footnote-271-4\" class=\"return-footnote\" aria-label=\"Return to footnote 4\">&crarr;<\/a><\/li><\/ol><\/div>","protected":false},"author":103,"menu_order":8,"template":"","meta":{"pb_show_title":"on","pb_short_title":"","pb_subtitle":"","pb_authors":["open-resources-for-nursing-open-rn"],"pb_section_license":""},"chapter-type":[48],"contributor":[68],"license":[],"class_list":["post-271","chapter","type-chapter","status-publish","hentry","chapter-type-numberless","contributor-open-resources-for-nursing-open-rn"],"part":233,"_links":{"self":[{"href":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters"}],"about":[{"href":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-json\/wp\/v2\/types\/chapter"}],"author":[{"embeddable":true,"href":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-json\/wp\/v2\/users\/103"}],"version-history":[{"count":10,"href":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/271\/revisions"}],"predecessor-version":[{"id":2270,"href":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/271\/revisions\/2270"}],"part":[{"href":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/parts\/233"}],"metadata":[{"href":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/271\/metadata\/"}],"wp:attachment":[{"href":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-json\/wp\/v2\/media?parent=271"}],"wp:term":[{"taxonomy":"chapter-type","embeddable":true,"href":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapter-type?post=271"},{"taxonomy":"contributor","embeddable":true,"href":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-json\/wp\/v2\/contributor?post=271"},{"taxonomy":"license","embeddable":true,"href":"https:\/\/pressbooks.bccampus.ca\/nursingpharmacology\/wp-json\/wp\/v2\/license?post=271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}